Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03322462 · ClinicalTrials.gov registry record · Phase 2
Tau Screening Study in Patients With Early Symptomatic AD
A Phase 2 study, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
NCT03322462 is a Phase 2 study that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 155 participants.
The verdict
NCT03322462, a Phase 2 study, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
Study Summary
This protocol is designed to serve as a pre-screening study for subjects who are potentially eligible for Alzheimer's Disease (AD) therapeutic trials that require tau imaging for inclusion by means of a flortaucipir F18 Positron Emission Tomography (PET) scan.
Interventions
- DRUG Flortaucipir F18
- PROCEDURE Brain PET Scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2017-11-21 |
| Est. Completion | 2018-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03322462
The ClinicalTrials.gov registry entry for NCT03322462 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avid Radiopharmaceuticals, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Flortaucipir F18 is the first listed.
NCT03322462 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03322462 about?
NCT03322462 is a clinical study titled "Tau Screening Study in Patients With Early Symptomatic AD". This protocol is designed to serve as a pre-screening study for subjects who are potentially eligible for Alzheimer's Disease (AD) therapeutic trials that require tau imaging for inclusion by means of a flortaucipir F18 Positron Emission Tomography (PET) scan.
What is the current status of trial NCT03322462?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2017-11-21. Estimated completion is 2018-08-31.
What interventions are being tested in trial NCT03322462?
The interventions under investigation include: Flortaucipir F18 (DRUG), Brain PET Scan (PROCEDURE).
Who is sponsoring clinical trial NCT03322462?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.